Autolus Therapeutics Ltd (AUTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has a cash flow conversion efficiency ratio of -0.600x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.32 Million) by net assets ($108.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Autolus Therapeutics Ltd stock valuation for the company's overall valuation and market capitalisation.
Autolus Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Autolus Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics Ltd ranked by their cash flow conversion efficiency. See Autolus Therapeutics Ltd cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock MIT II
NYSE:BLE
|
-0.063x |
|
Shenzhen King Explorer Science and Technology Corp Class A
SHE:002917
|
0.034x |
|
Laxmi Organic Industries Limited
NSE:LXCHEM
|
0.078x |
|
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
|
0.002x |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
0.070x |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
N/A |
|
Oncology Institute Inc
NASDAQ:TOI
|
0.136x |
|
Jiangxi Huawu Brake Co Ltd
SHE:300095
|
0.039x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics Ltd from 2015 to 2025. View AUTL live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $178.13 Million | $-283.57 Million | -1.592x | -229.79% |
| 2024-12-31 | $427.32 Million | $-206.27 Million | -0.483x | +63.04% |
| 2023-12-31 | $111.47 Million | $-145.59 Million | -1.306x | -247.32% |
| 2022-12-31 | $298.67 Million | $-112.31 Million | -0.376x | +0.04% |
| 2021-12-31 | $313.32 Million | $-117.86 Million | -0.376x | +32.91% |
| 2020-12-31 | $210.03 Million | $-117.76 Million | -0.561x | -40.79% |
| 2019-12-31 | $254.84 Million | $-101.48 Million | -0.398x | -216.06% |
| 2018-12-31 | $205.14 Million | $-25.85 Million | -0.126x | 0.00% |
| 2018-09-30 | $205.14 Million | $-25.85 Million | -0.126x | -9.83% |
| 2017-12-31 | $142.60 Million | $-16.36 Million | -0.115x | +64.25% |
| 2016-12-31 | $30.69 Million | $-9.85 Million | -0.321x | -99.85% |
| 2015-12-31 | $20.71 Million | $-3.33 Million | -0.161x | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more